

Special Issue

Advancements in Understanding and Treating Oral Pathologies: From Dry Mouth to Oral Cancer

Message from the Guest Editors

This Special Issue explores various aspects of the pathogenesis of oral diseases, emphasizing therapeutic interventions rooted in pathogenicity and providing examples that showcase the ways in which the pathogenesis of specific oral conditions reflects the interconnected nature of oral and general health. The central goal aligns with the World Health Organization's objective for promoting oral health, as outlined in the 2021 Resolution. Recent advancements in understanding and treating oral pathologies, ranging from common issues such as dry mouth (xerostomia) and taste disorders (dysgeusia) to severe conditions such as oral cancer and precancerous lesions, constitute the core focus. This broader perspective incorporates recommendations regarding environmental, genetic and social factors, aiming to provide a more comprehensive and understandable view of the subject. Additionally, dental treatments can offer valuable insights into general pathology, showcasing the interdisciplinary nature of oral healthcare. The Special Issue invites original research articles, reviews.

Guest Editors

Dr. Eleni Georgakopoulou

Research Fellow at the Laboratory of Histology-Embryology, University of Athens (Molecular Carcinogenesis Group), Athens, Greece

Prof. Dr. George Laskaris

School of Medicine, University of Athens, Athens, Greece

Deadline for manuscript submissions

31 March 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/201051

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).